Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

Barrett-Connor, 1985, Diabetes and heart disease, 41 Stamler, 1993, Diabetes and other risk factors and the 12-year cardiovascular mortality for men screened for the Multiple Risk Factor Intervention Trial, Diabetes Care, 16, 434, 10.2337/diacare.16.2.434 Zuanetti, 1993, Influence of diabetes on mortality in acute myocardial infarction: data from the GISSI-2 study, J Am Coll Cardiol, 22, 1788, 10.1016/0735-1097(93)90758-S Keech, 2003, Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial, Diabetes Care, 26, 2713, 10.2337/diacare.26.10.2713 Laakso, 1985, Serum lipids and lipoproteins in middle aged non-insulin dependent diabetics, Atherosclerosis, 56, 271, 10.1016/0021-9150(85)90003-6 Feingold, 1992, LDL subclass phenotypes and triglyceride metabolism in non-insulin dependent diabetes, Arterioscler Thromb, 12, 1496, 10.1161/01.ATV.12.12.1496 Wilson, 1985, Lipids, glucose intolerance and vascular disease: The Framingham Study, Monogr Atheroscler, 13, 1 Taskinen, 2003, Diabetic dyslipidaemia: from basic research to clinical practice, Diabetologia, 46, 733, 10.1007/s00125-003-1111-y Fontbonne, 1989, Hypertriglyceridemia as a risk factor for coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes, Diabetologia, 32, 300, 10.1007/BF00265546 Assmann, 1991, Triglycerides and atherosclerosis; results from the Prospective Cardiovascular Munster Study, Arterioscler Rev, 22, 51 Keating, 2002, Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia, Drugs, 62, 1909, 10.2165/00003495-200262130-00013 Frick, 1987, Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia—safety treatment, changes in risk factors, and incidence of coronary heart disease, N Engl J Med, 317, 1237, 10.1056/NEJM198711123172001 Koskinen, 1992, Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study, Diabetes Care, 15, 820, 10.2337/diacare.15.7.820 Rubins, 2002, Diabetes, plasma insulin and cardiovascular disease. Subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT), Arch Intern Med, 162, 2597, 10.1001/archinte.162.22.2597 Tenenbaum, 2005, Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome, Arch Intern Med, 165, 1154, 10.1001/archinte.165.10.1154 Elkeles, 1998, Cardiovascular outcomes in type 2 diabetes: a double-blind placebo-controlled study of bezafibrate—the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study, Diabetes Care, 21, 641, 10.2337/diacare.21.4.641 2001, Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study, Lancet, 357, 905, 10.1016/S0140-6736(00)04209-4 2004, The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, Cardiovasc Diabetol, 3, 9, 10.1186/1475-2840-3-9 Signorini, 1993, Dynamic balanced randomization for clinical trials, Stat Med, 12, 2343, 10.1002/sim.4780122410 2003, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial, Lancet, 361, 2005, 10.1016/S0140-6736(03)13636-7 2005, Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, a randomized, placebo-controlled trial: baseline characteristics and short-term effects of fenofibrate, Cardiovasc Diabetol, 4, 13, 10.1186/1475-2840-4-13 2001, Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults, JAMA, 285, 2487 Peto, 1976, Design and analysis of randomised clinical trials requiring prolonged observation of each patient. I. Introduction and design, Br J Cancer, 34, 585, 10.1038/bjc.1976.220 Peto, 1977, Design and analysis of randomised clinical trials requiring prolonged observation of each patient, 2: analysis and examples, Br J Cancer, 35, 1, 10.1038/bjc.1977.1 Collett, 1994 Studer, 2005, Effect of different antilipidemic agents and diets on mortality: a systemic review, Arch Intern Med, 165, 725, 10.1001/archinte.165.7.725 2005, Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins, Lancet, 366, 1267, 10.1016/S0140-6736(05)67394-1 Gami, 2003, Systematic review of lipid lowering for primary prevention of coronary heart disease in diabetes, BMJ, 326, 528, 10.1136/bmj.326.7388.528 Colhoun, 2004, Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial, Lancet, 364, 685, 10.1016/S0140-6736(04)16895-5 Syvanne, 2004, Serum homocysteine concentrations, gemfibrozil treatment, and progression of coronary atherosclerosis, Atherosclerosis, 172, 267, 10.1016/j.atherosclerosis.2003.10.003 2002, Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis, JAMA, 288, 2015, 10.1001/jama.288.16.2015 Hottelart, 2002, Fenofibrate increases creatininemia by increasing metabolic production of creatinine, Nephron, 92, 536, 10.1159/000064083 Heady, 1992, WHO clofibrate/cholesterol trial: clarifications, Lancet, 340, 1405, 10.1016/0140-6736(92)92588-7 Ansquer, 2005, Fenofibrate reduces progression to microalbuminuria over 3 years in the placebo-controlled study in type 2 diabetes: results from Diabetes Atherosclerosis Intervention Study (DAIS), Am J Kidney Dis, 45, 485, 10.1053/j.ajkd.2004.11.004